Skip to main content
. Author manuscript; available in PMC: 2011 Jan 4.
Published in final edited form as: FEBS Lett. 2010 Jan 4;584(1):141–146. doi: 10.1016/j.febslet.2009.11.031

Fig. 1.

Fig. 1

VEGF translocates NFATc1 into the nucleus and CsA inhibits the activation. A. HPVECs were stimulated with 50 ng/ml VEGF for 30 min (b) or for 3 h (c) or CsA (1 μM) plus VEGF for 30 min (d). Cells were incubated with a mouse control IgG (a) or with mouse anti-human NFATc1 (b-d), followed by anti-mouse conjugated FITC. In panel d, HPVECs were preincubated with 1 μM CsA for 2 h prior to addition of VEGF. Photographs were taken at 630× magnification. B. Cell lysates from HPVEC in EBM-2 with growth factors (lane 1), EBM-2 without growth factor (lane 2-8) were analyzed for the expression of NFATc1 by western blot. Cells were treated with VEGF 50 ng in the absence (lane 2, 4, 6) or presence (lane 3, 5, 7, 8) of 1 μM CsA for indicated times. Alpha-tubulin levels in each cell lysate are shown as a control.